Targeting STE20-type kinase MST3 improves metabolic dysfunction-associated steatohepatitis without affecting...

Area of Science:

• Hepatology
• Oncology
• Metabolic Diseases

Background:

• Metabolic dysfunction-associated steatohepatitis (MASH) is a key driver of hepatocellular carcinoma (HCC).
• The molecular links between MASH and HCC development are not fully understood.
• MST3 kinase is involved in liver metabolic homeostasis and stress responses.

Purpose of the Study:

• To investigate if inhibiting MST3 kinase can prevent MASH-associated HCC.
• To explore the role of MST3 in MASH and liver cancer progression.
• To understand the molecular mechanisms underlying MST3's function in the liver.

Main Methods:

• A mouse model of MASH-HCC was established using diethylnitrosamine and a Western-style diet.
• Mst3-targeting antisense oligonucleotide (ASO) was administered to inhibit MST3.
• Liver tumor burden, histology, and biochemistry were assessed.
• Proteomic profiling of MST3 knockout hepatocytes was performed.

Main Results:

• MST3 inhibition did not affect MASH-associated HCC onset or progression.
• MST3 ASO therapy significantly improved metabolic profiles and reduced MASH features.
• MST3 deficiency activated mitochondrial and lysosomal pathways for fatty acid degradation.

Conclusions:

• MST3 is dispensable for MASH-associated hepatocarcinogenesis in this model.
• MST3 antagonism ameliorates diet-induced metabolic dysfunction and MASH.
• Targeting MASH alone may be insufficient to prevent HCC in obesity contexts.